ProQR Historical Income Statement

PRQR Stock

USD 3.67 0.23 6.69%

Historical analysis of ProQR Therapeutics income statement accounts such as Depreciation And Amortization of 2.6 M, Selling General Administrative of 12.6 M, Gross Profit of 6.7 M or Other Operating Expenses of 45.3 M can show how well ProQR Therapeutics BV performed in making a profits. Evaluating ProQR Therapeutics income statement over time to spot trends is a great complementary tool to traditional technical analysis and can indicate the direction of ProQR Therapeutics's future profits or losses.

Cash Flow Balance Sheet Income Statement

Yuan Drop

Covid

Financial Statement Analysis is much more than just reviewing and examining ProQR Therapeutics latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether ProQR Therapeutics is a good buy for the upcoming year.

Net Income Gross Profit

Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in ProQR Therapeutics BV. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in producer price index.

About ProQR Income Statement Analysis

ProQR Therapeutics Income Statement consists of revenues and expenses along with the resulting net income or loss. It represents the profit for the accounting period attributable to ProQR Therapeutics shareholders. The income statement also shows ProQR investors and management if the firm made money during the period reported. The result of an income statement is the net income that is calculated after subtracting the expenses from revenue. It is essential to investors both as an absolute measure as well as earnings per share (i.e., EPS).

ProQR Therapeutics Income Statement Chart

At this time, ProQR Therapeutics' Total Other Income Expense Net is relatively stable compared to the past year. As of 11/29/2024, Interest Income is likely to grow to about 2.7 M, while Selling General Administrative is likely to drop slightly above 12.6 M.

Research Development Selling General Administrative Other Operating Expenses Total Operating Expenses Total Other Income Expense Net

Other Operating Expenses

Other Operating Expenses is the expense which generally does not depend on sales or production quantities of ProQR Therapeutics. It is also known as ProQR Therapeutics overhead expenses. Typically these expenses include marketing, rent and utilities, office, leases, and other overhead cost. Expenses incurred from non-core business activities, including administrative and general expenses, but excluding costs directly related to production.

Total Operating Expenses

The total costs associated with the day-to-day operations of a business, excluding the cost of goods sold but including selling, general, and administrative expenses.

Most accounts from ProQR Therapeutics' income statement are interrelated and interconnected. However, analyzing income statement accounts one by one will only give a small insight into ProQR Therapeutics current financial condition. On the other hand, looking into the entire matrix of income statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in ProQR Therapeutics BV. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in producer price index.

ProQR Therapeutics income statement Correlations

	Interest Expense	Total Revenue	Research Development	Cost Of Revenue	Depreciation And Amortization	Selling General Administrative	Gross Profit	Other Operating Expenses	Operating Income	Net Income From Continuing Ops	Ebit	Ebitda	Total Operating Expenses	Income Before Tax	Total Other Income Expense Net	Net Income	Income Tax Expense	Minority Interest	Interest Income	Net Interest Income	Reconciled Depreciation	Selling And Marketing Expenses
Interest Expense		0.19	0.76	-0.1	0.76	0.79	0.01	0.78	-0.78	-0.78	-0.56	-0.54	0.78	-0.79	-0.23	-0.79	0.24	-0.26	-0.63	-0.77	0.78	-0.06
Total Revenue	0.19		0.31	-0.34	0.42	0.39	0.15	0.33	-0.26	-0.21	-0.01	0.01	0.33	-0.15	0.67	-0.15	-0.42	-0.29	-0.06	0.22	0.28	-0.51
Research Development	0.76	0.31		0.11	0.57	0.92	-0.33	1.0	-0.99	-0.98	-0.74	-0.73	1.0	-0.98	0.01	-0.98	0.15	-0.5	-0.89	-0.5	0.69	-0.1
Cost Of Revenue	-0.1	-0.34	0.11		-0.2	0.06	0.04	0.1	-0.13	-0.16	-0.03	-0.04	0.1	-0.17	0.05	-0.17	0.09	0.19	-0.27	0.05	-0.21	0.1
Depreciation And Amortization	0.76	0.42	0.57	-0.2		0.75	0.2	0.62	-0.55	-0.52	-0.5	-0.47	0.62	-0.53	-0.1	-0.53	0.21	-0.47	-0.44	-0.35	0.91	-0.57
Selling General Administrative	0.79	0.39	0.92	0.06	0.75		-0.13	0.95	-0.92	-0.9	-0.66	-0.65	0.95	-0.9	0.09	-0.9	0.18	-0.51	-0.84	-0.41	0.79	-0.27
Gross Profit	0.01	0.15	-0.33	0.04	0.2	-0.13		-0.29	0.34	0.32	0.19	0.19	-0.29	0.33	0.1	0.33	-0.17	0.45	0.22	-0.03	-0.19	-0.15
Other Operating Expenses	0.78	0.33	1.0	0.1	0.62	0.95	-0.29		-0.99	-0.98	-0.73	-0.72	1.0	-0.97	0.03	-0.97	0.17	-0.51	-0.89	-0.49	0.72	-0.15
Operating Income	-0.78	-0.26	-0.99	-0.13	-0.55	-0.92	0.34	-0.99		0.99	0.7	0.69	-0.99	0.99	0.02	0.99	-0.16	0.43	0.89	0.52	-0.67	0.04
Net Income From Continuing Ops	-0.78	-0.21	-0.98	-0.16	-0.52	-0.9	0.32	-0.98	0.99		0.73	0.72	-0.98	1.0	0.09	1.0	-0.17	0.38	0.89	0.58	-0.64	-0.04
Ebit	-0.56	-0.01	-0.74	-0.03	-0.5	-0.66	0.19	-0.73	0.7	0.73		1.0	-0.73	0.73	0.4	0.73	-0.15	0.61	0.71	0.64	-0.59	-0.1
Ebitda	-0.54	0.01	-0.73	-0.04	-0.47	-0.65	0.19	-0.72	0.69	0.72	1.0		-0.72	0.72	0.4	0.72	-0.15	0.61	0.71	0.64	-0.57	-0.12
Total Operating Expenses	0.78	0.33	1.0	0.1	0.62	0.95	-0.29	1.0	-0.99	-0.98	-0.73	-0.72		-0.97	0.03	-0.97	0.17	-0.51	-0.89	-0.49	0.72	-0.15
Income Before Tax	-0.79	-0.15	-0.98	-0.17	-0.53	-0.9	0.33	-0.97	0.99	1.0	0.73	0.72	-0.97		0.11	1.0	-0.24	0.4	0.92	0.58	-0.66	-0.02
Total Other Income Expense Net	-0.23	0.67	0.01	0.05	-0.1	0.09	0.1	0.03	0.02	0.09	0.4	0.4	0.03	0.11		0.11	-0.18	-0.11	0.0	0.58	-0.2	-0.46
Net Income	-0.79	-0.15	-0.98	-0.17	-0.53	-0.9	0.33	-0.97	0.99	1.0	0.73	0.72	-0.97	1.0	0.11		-0.24	0.4	0.92	0.58	-0.66	-0.02
Income Tax Expense	0.24	-0.42	0.15	0.09	0.21	0.18	-0.17	0.17	-0.16	-0.17	-0.15	-0.15	0.17	-0.24	-0.18	-0.24		-0.26	-0.45	-0.15	0.33	-0.13
Minority Interest	-0.26	-0.29	-0.5	0.19	-0.47	-0.51	0.45	-0.51	0.43	0.38	0.61	0.61	-0.51	0.4	-0.11	0.4	-0.26		0.42	0.06	-0.64	0.4
Interest Income	-0.63	-0.06	-0.89	-0.27	-0.44	-0.84	0.22	-0.89	0.89	0.89	0.71	0.71	-0.89	0.92	0.0	0.92	-0.45	0.42		0.44	-0.53	0.03
Net Interest Income	-0.77	0.22	-0.5	0.05	-0.35	-0.41	-0.03	-0.49	0.52	0.58	0.64	0.64	-0.49	0.58	0.58	0.58	-0.15	0.06	0.44		-0.4	-0.49
Reconciled Depreciation	0.78	0.28	0.69	-0.21	0.91	0.79	-0.19	0.72	-0.67	-0.64	-0.59	-0.57	0.72	-0.66	-0.2	-0.66	0.33	-0.64	-0.53	-0.4		-0.42
Selling And Marketing Expenses	-0.06	-0.51	-0.1	0.1	-0.57	-0.27	-0.15	-0.15	0.04	-0.04	-0.1	-0.12	-0.15	-0.02	-0.46	-0.02	-0.13	0.4	0.03	-0.49	-0.42

Click cells to compare fundamentals

ProQR Therapeutics Account Relationship Matchups

ProQR Therapeutics income statement Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Interest Expense	1.1M	2.0M	3.4M	5.1M	1.2M	1.4M
Total Revenue	1.9M	243K	1.4M	4.0M	6.5M	6.8M
Research Development	46.5M	38.1M	42.2M	50.9M	25.1M	30.4M
Cost Of Revenue	0.0	116.8M	2.2M	2.5M	133.5K	126.8K
Depreciation And Amortization	171.9K	2.2M	2.4M	2.5M	2.5M	2.6M
Selling General Administrative	12.9M	13.7M	17.4M	18.7M	16.2M	12.6M
Gross Profit	(114.9M)	(2.2M)	1.4M	1.6M	6.4M	6.7M
Other Operating Expenses	59.4M	51.8M	58.5M	68.8M	38.4M	45.3M
Operating Income	(57.4M)	(42.4M)	(57.2M)	(64.7M)	(31.9M)	(33.5M)
Net Income From Continuing Ops	(56.7M)	(46.6M)	(61.7M)	(64.9M)	(27.7M)	(29.1M)
Ebit	(57.5M)	(138.8M)	(57.4M)	(58.9M)	(26.6M)	(27.9M)
Ebitda	(57.3M)	(136.6M)	(54.9M)	(56.5M)	(24.1M)	(25.3M)
Total Operating Expenses	59.4M	51.8M	58.5M	68.8M	38.4M	45.3M
Income Before Tax	(56.6M)	(46.5M)	(61.6M)	(64.8M)	(27.8M)	(29.2M)
Total Other Income Expense Net	831K	(4.1M)	(3.5M)	1.1M	4.0M	4.2M
Net Income Applicable To Common Shares	(56.5M)	(46.6M)	(61.6M)	(65.1M)	(58.6M)	(61.5M)
Net Income	(56.7M)	(46.6M)	(61.7M)	(64.9M)	(28.1M)	(29.5M)
Income Tax Expense	132K	124K	117K	96K	(78K)	(81.9K)
Minority Interest	(496K)	(545K)	59K	(220K)	(384K)	(364.8K)
Interest Income	763K	313K	5K	106K	2.6M	2.7M
Tax Provision	132K	124K	117K	96K	(78K)	(74.1K)
Net Interest Income	(320K)	(3.7M)	(2.8M)	(5.0M)	1.4M	1.5M
Reconciled Depreciation	2.1M	2.4M	2.3M	2.5M	2.5M	2.2M

Pair Trading with ProQR Therapeutics

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if ProQR Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in ProQR Therapeutics will appreciate offsetting losses from the drop in the long position's value.

Moving together with ProQR Stock

0.76	ESPR	Esperion Therapeutics	Pair Corr
0.76	EWTX	Edgewise Therapeutics	Pair Corr

Moving against ProQR Stock

0.83	MRK	Merck Company Fiscal Year End 6th of February 2025	Pair Corr
0.81	HLN	Haleon plc	Pair Corr
0.77	TAK	Takeda Pharmaceutical	Pair Corr
0.74	ELAN	Elanco Animal Health Potential Growth	Pair Corr
0.67	RDY	Dr Reddys Laboratories	Pair Corr

The ability to find closely correlated positions to ProQR Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace ProQR Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back ProQR Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling ProQR Therapeutics BV to buy it.

The correlation of ProQR Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as ProQR Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if ProQR Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.

Correlation analysis and pair trading evaluation for ProQR Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.

Pair Correlation Correlation Matching

Additional Tools for ProQR Stock Analysis

When running ProQR Therapeutics' price analysis, check to measure ProQR Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy ProQR Therapeutics is operating at the current time. Most of ProQR Therapeutics' value examination focuses on studying past and present price action to predict the probability of ProQR Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move ProQR Therapeutics' price. Additionally, you may evaluate how the addition of ProQR Therapeutics to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

ProQR Historical Income Statement

About ProQR Income Statement Analysis

ProQR Therapeutics Income Statement Chart

Other Operating Expenses

Total Operating Expenses

ProQR Therapeutics income statement Correlations

ProQR Therapeutics Account Relationship Matchups

High Positive Relationship

High Negative Relationship

ProQR Therapeutics income statement Accounts

Pair Trading with ProQR Therapeutics

Moving together with ProQR Stock

Moving against ProQR Stock

Additional Tools for ProQR Stock Analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Other Operating Expenses	+ 1.0	Research Development
Total Operating Expenses	+ 1.0	Research Development
Total Operating Expenses	+ 1.0	Other Operating Expenses
Income Before Tax	+ 1.0	Net Income From Continuing Ops
Net Income	+ 1.0	Net Income From Continuing Ops
Ebitda	+ 1.0	Ebit

Total Operating Expenses	- 0.99	Operating Income
Operating Income	- 0.99	Other Operating Expenses
Operating Income	- 0.99	Research Development
Total Operating Expenses	- 0.98	Net Income From Continuing Ops
Net Income From Continuing Ops	- 0.98	Other Operating Expenses
Net Income	- 0.98	Research Development